Canopy Growth vs. Tilray Brands: Quarterly Revenue Scale and Consistency in Cannabis
Canopy Growth: Tracking Uneven Quarterly Revenue Patterns
Canopy Growth (CGC -4.52%) primarily generates revenue by selling medical and recreational cannabis products to consumers across several international regions.
CGC – Canopy Growth
$0.64-$0.03 (-4.52%)
NASDAQ · As of 3:03 PM ET 10/30/26
It recently secured renewed European Union manufacturing certifications for multiple Canadian facilities to support its supply chain, and it expanded its international medical cannabis operations by launching new product formats in Australia, supplying four Canadian-grown flower strains to the United Kingdom, and appointing a dedicated country manager for its growing business in Germany.
Tilray Brands: Observing Upward Quarterly Revenue Trends
Tilray Brands (TLRY -5.30%) earns most of its revenue by selling cannabis, alcoholic beverages, and various wellness products globally.
TLRY – Tilray Brands
$2.50-$0.14 (-5.30%)
NASDAQ · As of 3:05 PM ET 10/30/26
It recently expanded its total annual cannabis production capacity to approximately 275 metric tonnes across its cultivation facilities in Canada and Portugal, and its beverage division secured new regional distribution agreements for its craft spirits while finalizing multiple professional sports partnerships for its brands across the United States and the United Kingdom.
Why Revenue Matters for Investors
Revenue here refers to the data provider’s standardized income-statement revenue line item, and it provides a baseline measurement of customer demand before business expenses are deducted.
Canopy Growth vs. Tilray Brands Revenue over the last 8 quarters. Figures: Canopy Growth shown in U.S. dollars, converted from Canadian dollars.
Comparing Quarterly Revenue for Canopy Growth and Tilray Brands
Calendar quarterCanopy Growth RevenueTilray Brands RevenueQ4 2024$53.5 million (quarter ended Dec. 31, 2024)$210.9 million (quarter ended Nov. 30, 2024)Q1 2025$45.3 million (quarter ended March 31, 2025)$185.8 million (quarter ended Feb. 28, 2025)Q2 2025$52.1 million (quarter ended June 30, 2025)$224.5 million (quarter ended May 31, 2025)Q3 2025$48.4 million (quarter ended Sept. 30, 2025)$209.5 million (quarter ended Aug. 31, 2025)Q4 2025$73.3 million (quarter ended Dec. 31, 2025)$217.5 million (quarter ended Nov. 30, 2025)Q1 2026$51.9 million (quarter ended March 31, 2026)$206.7 million (quarter ended Feb. 28, 2026)Q2 2026$58.6 million (quarter ended June 30, 2026)$281.7 million (quarter ended May 31, 2026)Q3 2026Not yet reported$257.1 million (quarter ended Aug. 31, 2026)
Foolish Take
Normally, the first thing to note when examining a company’s revenue trend is seasonality: some times of the year have stronger buying patterns than others. For most stocks, compare revenue year over year, by quarter. Even as a relatively new business sector, there is seasonality in cannabis, with sales seeing periodic strength during the summer months and especially April 20, given the calendar date is a well-known marijuana pop culture reference.
When viewing the chart for both Tilray and Canopy Growth from left to right, it may seem revenue is volatile, but in fact, viewed quarterly against the prior year’s comparable quarter, there is steady growth for both.
Revenue is probably the simplest metric investors have to judge a business by. It is also one of the most important ones. As the chart shows, look for rising revenue over similar periods of each year, and take comparable-quarter stagnation, or worse, declines, as a red flag.
Data source: Financial Modeling Prep. Canopy Growth’s figures are converted from Canadian dollars to U.S. dollars. Data as of Oct. 22, 2026.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.